Copper Eye Drops for Corneal Cross-Linking in Myopia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Myopia, characterized by a slightly elongated eyeball causing light focus in front of the retina, leads to impaired distance vision and increases the risk of retinal detachment, cataracts, and glaucoma, with a rising global prevalence.
Innovation Solution
Administration of a therapeutically effective amount of a copper-containing agent, such as copper sulfate, to increase lysyl oxidase activity and enhance corneal cross-linking, thereby increasing corneal stiffness and flattening the myopic cornea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If copper-containing agent is administered to increase corneal stiffness, then myopic progression is reduced, but corneal over-flattening and irregular astigmatism may occur
Solution Approach 1:
The patent applies parameter changes by carefully controlling the concentration of copper-containing agent (0.001% to 0.01%) and the treatment frequency (1-4 times daily) to achieve optimal corneal stiffening while avoiding excessive flattening. The treatment duration is also controlled (4-16 weeks) to prevent over-correction and irregular astigmatism development.
2Strength
If copper-containing agent is administered to enhance corneal cross-linking, then corneal biomechanical properties are improved, but potential toxicity and side effects may arise
Solution Approach 1:
The patent uses parameter changes by optimizing the copper-containing agent concentration within a safe range (0.001% to 0.01%) that is sufficient to enhance corneal cross-linking and biomechanical properties but low enough to avoid copper toxicity and adverse side effects. This controlled dosing strategy balances therapeutic efficacy with safety.
3Measurement precision
If traditional myopia treatments are used, then distance vision is corrected, but myopic progression continues and complications risk increases
Solution Approach 1:
The patent applies preliminary action by administering copper-containing eye drops before significant myopic progression or complications occur. The treatment proactively strengthens corneal biomechanical properties and reduces axial elongation tendencies, preventing further myopia development and associated complications rather than merely correcting the refractive error.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The copper treatment enhances corneal biomechanical properties, reducing myopic progression and potentially preventing complications like retinal detachment and cataracts.
Implementation Method 1
increase lysyl oxidase activity in an eye of a subject or otherwise increase corneal cross-linking
Implementation Method 2
enhance corneal cross-linking, thereby increasing corneal stiffness
Data Source
AI summary
An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.